Cover Image
Market Research Report
Product code 
1045334

Therapeutics for Women's Health: Technologies and Global Markets

Published: | BCC Research | 258 Pages | Delivery time: 1-2 business days

Price

Back to Top
Therapeutics for Women's Health: Technologies and Global Markets
Published: January 5, 2022
BCC Research
Content info: 258 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Highlights:

The global market for women’s health therapeutics should grow from $54.4 billion in 2021 to $70.8 billion by 2026 with a compound annual growth rate (CAGR) of 5.4% for the period of 2021-2026.

North American market for women’s health therapeutics should grow from $21.0 billion in 2021 to $27.1 billion by 2026 with a compound annual growth rate (CAGR) of 5.2% for the period of 2021-2026.

European market for women’s health therapeutics should grow from $17.7 billion in 2021 to $23.0 billion by 2026 with a compound annual growth rate (CAGR) of 5.5% for the period of 2021-2026.

Report Scope:

This report is an analytical business tool that comprehensively evaluates the global market for women's health therapeutics. The format of the study is organized around the following topics -

  • Detailed study around women's diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
  • Disease incidence and prevalence.
  • Regulatory structure of pharmaceutical industry.
  • Market characterization, unmet need, market size and segmentation.
  • Market drivers and restraints.
  • Detailed market projections through 2026.
  • Competition and market shares.
  • Pricing and reimbursement.
  • Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
  • Observations and conclusions regarding the future of market for women's health therapeutics.
  • Profiles of market participants and associations.

Report Includes:

  • 58 data tables and 56 additional tables
  • An overview of the global market and technologies for women's health therapeutics
  • Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
  • Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
  • Discussion on aging and women's health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
  • Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck
Table of Contents
Product Code: BIO043G

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • What's New in this Update?
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview of Technologies and Global Markets

  • Disease Overview and Definitions
  • Historical Background
  • Market Driving Factors and Opportunities
  • Aging Female Population
  • Government Involvement and Increased Funding
  • Increasing Awareness Regarding Women's Disorders and Treatments
  • Market Restraints
  • Poor Diagnosis
  • Availability of Alternate Treatment Options and Lifestyle Changes
  • Unavailability of Novel Treatments
  • High Treatment Cost of Osteoporosis
  • Opportunities
  • Rising Female Population in Asia-Pacific
  • Increased Demand for Technology Innovation
  • Mergers and Acquisitions

Chapter 4 Impact of COVID-19 Pandemic

  • Implications on Women's Health and Diagnosis
  • Implications on Cancer Treatment
  • Impact on Oncology Pharmaceuticals Market

Chapter 5 Pipeline Assessment and Analysis

  • Women's Health Therapeutics: Key Clinical Trial Developments
  • List of Drugs in Pipeline
  • Overview of Osteoporosis Drug Development Pipeline
  • Late-stage Pipeline Drugs

Chapter 6 Regulatory Structure

  • Overview of Regulations
  • U.S.
  • Canada
  • Europe
  • Japan

Chapter 7 Market Breakdown by Women's Health Disorder

  • Introduction
  • Menopause-Related Diseases
  • Overview
  • Symptoms
  • Risk Factors
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecast
  • Postmenopausal Osteoporosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Endometriosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Polycystic Ovary Syndrome
  • Overview
  • Etiology
  • Reducing PCOS Risk
  • Epidemiology and Economic Burden
  • Disease Symptoms and Risk Factors
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Breast Cancer
  • Overview
  • Market Size and Forecasts

Chapter 8 Market Breakdown by Region

  • Introduction
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
  • Rest of the World
  • South America
  • Middle East and Africa

Chapter 9 Pricing and Reimbursement

  • Overview of Pricing and Reimbursement
  • U.S.
  • Canada
  • Europe
  • Japan

Chapter 10 Competitive Landscape and Key Developments

  • Market Players and Strategies
  • Blockbuster Breast Cancer Pharmaceutical Brands
  • Patent Analysis
  • List of Key Patents
  • Key Developments
  • Mergers and Acquisitions
  • Development of Innovative Products/Novel Product Launch
  • Agreements, Collaborations and Partnerships
  • Key Products

Chapter 11 Company Profiles

  • ABBVIE INC.
  • AMGEN INC.
  • ASAHI KASEI
  • ASTRAZENECA PLC
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • DAIICHI SANKYO CO. LTD.
  • ELI LILLY AND CO.
  • EISAI
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • JOHNSON & JOHNSON SERVICES INC.
  • MERCK & CO. INC.
  • MERCK KGAA
  • NOVARTIS AG
  • NOVO NORDISK
  • PFIZER INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO. LTD.

Chapter 12 Conclusions: Outlook for Women's Health Therapeutics

  • Major Developments to Influence Market
  • Therapeutic Developments
  • Demographic and Economic Trends
  • Income Growth in Emerging Markets
  • Future Outlook

Chapter 13 Appendix A: Glossary of Terms

Chapter 14 Appendix B: Industry and Professional Organizations

Chapter 15 Appendix C: Acronyms Used in This Report

  • Acronyms Used in This Report

List of Tables

  • Summary Table A : Global Market for Women's Health Therapeutics and Technologies, by Disease Area, Through 2026
  • Summary Table B : Global Market for Women's Health Therapeutics, by Region, Through 2026
  • Table 1 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated)
  • Table 2 : Recent M&A Deals in the Global Market for Women's Health Therapeutics, 2019-2021
  • Table 3 : Novel Breast Cancer Drug Approvals
  • Table 4 : Selected New Breast Cancer Drugs in Late Stages of Clinical Development
  • Table 5 : Pipeline Molecules, Endometriosis
  • Table 6 : Pipeline Molecules, Uterine Fibroids
  • Table 7 : Pipeline Molecules, All Other Indications
  • Table 8 : Pipeline Molecules, Osteoporosis
  • Table 9 : Elagolix Snapshot
  • Table 10 : Vilaprisan Snapshot
  • Table 11 : Evenity Snapshot
  • Table 12 : Relugolix Snapshot
  • Table 13 : Proellex Snapshot
  • Table 14 : Esmya Snapshot
  • Table 15 : TX-004HR Snapshot
  • Table 16 : TX-001HR Snapshot
  • Table 17 : Global Market for Women's Health Therapeutics and Technologies, by Disease Area, Through 2026
  • Table 18 : FDA Approved Estrogen-only Medicines
  • Table 19 : FDA Approved Progestin-Only Medicines
  • Table 20 : FDA Approved Combination, Estrogen and Progestin Medicines
  • Table 21 : FDA Approved Combination Estrogen and Hormone Medicines
  • Table 22 : Vagifem (10mcg), Patent Expiration
  • Table 23 : Global Market for Menopause Therapeutics, by Region, Through 2026
  • Table 24 : Prolia/XGEVA (Denosumab) Patent Expiration
  • Table 25 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026
  • Table 26 : Global Market for Endometriosis Therapeutics, by Region, Through 2026
  • Table 27 : Commonly Prescribed Generic Drugs for the Treatment of PCOS
  • Table 28 : Global Market for PCOS Therapeutics, by Region, Through 2026
  • Table 29 : TNM Classifications of Breast Cancers
  • Table 30 : Global Breast Cancer Incidence, 2016-2021
  • Table 31 : Global Breast Cancer Incidence and Mortality, by Region, 2018
  • Table 32 : Types of Hormone Therapy for Breast Cancer
  • Table 33 : Drugs Commonly Used to Treat Breast Cancer
  • Table 34 : Global Market for Breast Cancer Therapeutics, by Region, Through 2026
  • Table 35 : Global Market for Women's Health Therapeutics, by Region, Through 2026
  • Table 36 : North American Market for Women's Health Therapeutics, by Country, Through 2026
  • Table 37 : North American Market for Women's Health Therapeutics, by Disease Area Through 2026
  • Table 38 : U.S. Market for Women's Health Therapeutics, by Disease Area Through 2026
  • Table 39 : Canadian Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 40 : Mexican Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 41 : European Market for Women's Health Therapeutics, by Country, Through 2026
  • Table 42 : European Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 43 : U.K. Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 44 : German Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 45 : French Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 46 : Spanish Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 47 : Italian Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 48 : Rest of the European Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 49 : Asia-Pacific Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 50 : RoW Market for Women's Health Therapeutics, by Sub-region Through 2026
  • Table 51 : RoW Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 52 : South American Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 53 : Middle East and African Market for Women's Health Therapeutics, by Disease Area, Through 2026
  • Table 54 : Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020
  • Table 55 : Major Women's Health Therapeutics Pharmaceuticals by Company Revenue, 2020
  • Table 56 : Global Market Shares of Women's Health Therapeutics, by Company Revenue, 2020
  • Table 57 : Patent Review, 2021
  • Table 58 : Novel Women's Health Therapeutic Drug Approvals, 2021
  • Table 59 : Selected New Women's Health Therapeutic Drugs in Late Stages of Clinical Development
  • Table 60 : Marketed Products, Postmenopausal Osteoporosis
  • Table 61 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 62 : AbbVie Inc.: Net Revenue, 2017-2020
  • Table 63 : AbbVie: Oncology Pharmaceutical Product Portfolio
  • Table 64 : AbbVie Inc.: Marketed Products
  • Table 65 : AbbVie Inc.: Key Developments, 2021
  • Table 66 : Allergan plc: Marketed Products
  • Table 67 : Allergan plc: Net Revenue, 2017-2019
  • Table 68 : Amgen: Oncology Pharmaceutical Product Portfolio
  • Table 69 : Amgen: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 70 : Amgen: Financials, 2014-2020
  • Table 71 : AstraZeneca: Oncology Pharmaceutical Product Portfolio
  • Table 72 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 73 : Bayer AG: Marketed Products
  • Table 74 : Bayer AG: Oncology Pharmaceutical Product Portfolio
  • Table 75 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 76 : Bayer AG: Net Revenue, 2018-2020
  • Table 77 : Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio
  • Table 78 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 79 : Daiichi Sankyo Co. Ltd.: Marketed Products
  • Table 80 : Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020
  • Table 81 : Eli Lilly and Co.: Marketed Osteoporosis Products
  • Table 82 : Eli Lilly and Co.: Net Revenue, 2018-2020
  • Table 83 : Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio
  • Table 84 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 85 : Roche: Oncology Pharmaceutical Product Portfolio
  • Table 86 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 87 : Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio
  • Table 88 : Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 89 : Johnson & Johnson: Oncology Pharmaceutical Product Portfolio
  • Table 90 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 91 : Johnson & Johnson Services Inc.: Net Revenue, 2017-2020
  • Table 92 : Merck & Co. Inc.: Marketed Products
  • Table 93 : Merck & Co. Inc.: Net Revenue, 2017-2019
  • Table 94 : Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio
  • Table 95 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 96 : Merck KGaA Marketed Products
  • Table 97 : Novartis: Oncology Pharmaceutical Product Portfolio
  • Table 98 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 99 : Novo Nordisk: Marketed Products
  • Table 100 : Novo Nordisk: Net Revenue, 2017-2019
  • Table 101 : Pfizer Inc.: Oncology Pharmaceutical Product Portfolio
  • Table 102 : Pfizer Inc.: Women's Health-Marketed Products, by Indication
  • Table 103 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
  • Table 104 : Pfizer Inc. Net Revenue, 2017-2019
  • Table 105 : Sanofi: Oncology Pharmaceutical Product Portfolio
  • Table 106 : Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
  • Table 107 : Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio
  • Table 108 : Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021
  • Table 109 : New Cancer Cases in the U.S., by Age Group, 2018
  • Table 110 : Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016
  • Table 111 : Glossary of Terms Used in Women's Health Therapeutics
  • Table 112 : Acronyms Used in Women's Health Therapeutics

List of Figures

  • Summary Figure A : Global Market for Women's Health Therapeutics, by Disease Area, 2020-2026
  • Summary Figure B : Global Market for Women's Health Therapeutics, by Region, 2020-2026
  • Figure 1 : Distribution of Global Elderly Population, by Age Group and Sex, 2020
  • Figure 2 : Distribution of Global Elderly Population, by Age Group and Sex, 2050
  • Figure 3 : Funding for Research in Women's Health, by Disease Condition/Category, 2014-2016
  • Figure 4 : Funding for Research in Women's Health, 2014-2016
  • Figure 5 : Distribution of Insurance Coverage in the U.S., by Type of Healthcare Provider, 2014
  • Figure 6 : Global Market for Women's Health Therapeutics, 2018-2026
  • Figure 7 : Global Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 8 : Global Market Shares of Women's Health Therapeutics, by Disease Area, 2026
  • Figure 9 : Global Market for Menopause Therapeutics, 2020-2026
  • Figure 10 : Global Market for Menopause Therapeutics, by Region, 2020-2026
  • Figure 11 : Rate of Hospitalization for Osteoporosis in Australia, by Age Group, 2015-2016
  • Figure 12 : Global Market for Postmenopausal Osteoporosis Therapeutics, 2020-2026
  • Figure 13 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, 2020-2026
  • Figure 14 : Global Market for Endometriosis Therapeutics, 2018-2026
  • Figure 15 : Global Market for Endometriosis Therapeutics, by Region, 2020-2026
  • Figure 16 : Global Market for PCOS Therapeutics, 2018-2026
  • Figure 17 : Global Market for PCOS Therapeutics, by Region, 2018-2026
  • Figure 18 : Global Market for Breast Cancer Therapeutics, 2018-2026
  • Figure 19 : Global Market for Breast Cancer Therapeutics, by Region, 2020-2026
  • Figure 20 : Global Market for Women's Health Therapeutics, by Region, 20202026
  • Figure 21 : North American Market Shares of Women's Health Therapeutics, by Country, 2020
  • Figure 22 : North American Market for Women's Health Therapeutics, 2018-2026
  • Figure 23 : North American Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 24 : North American Market for Women's Health Therapeutics, by Country, 2020-2026
  • Figure 25 : U.S. Market for Women's Health Therapeutics, 2018-2026
  • Figure 26 : Canadian Market for Women's Health Therapeutics, 2018-2026
  • Figure 27 : Mexican Market for Women's Health Therapeutics, 2018-2026
  • Figure 28 : European Market for Women's Health Therapeutics, by Country, 2020-2026
  • Figure 29 : European Market Shares of Women's Health Therapeutics, by Country, 2020
  • Figure 30 : European Market for Women's Health Therapeutics, 2018-2026
  • Figure 31 : European Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 32 : U.K. Market for Women's Health Therapeutics, 2018-2026
  • Figure 33 : German Market for Women's Health Therapeutics, 2018-2026
  • Figure 34 : French Market for Women's Health Therapeutics, 2018-2026
  • Figure 35 : Spanish Market for Women's Health Therapeutics, 2018-2026
  • Figure 36 : Italian Market for Women's Health Therapeutics, 2018-2026
  • Figure 37 : Rest of the European Market for Women's Health Therapeutics, 2018-2026
  • Figure 38 : Asia-Pacific Market for Women's Health Therapeutics, 2018-2026
  • Figure 39 : Asia-Pacific Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 40 : Asia-Pacific Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 41 : Asia-Pacific Market for Women's Health Therapeutics, by Disease Area, 2020-2026
  • Figure 42 : Chinese Market for Women's Health Therapeutics, 2018-2026
  • Figure 43 : Japanese Market for Women's Health Therapeutics, 2018-2026
  • Figure 44 : Indian Market for Women's Health Therapeutics, 2018-2026
  • Figure 45 : South Korean Market for Women's Health Therapeutics, 2018-2026
  • Figure 46 : Rest of Asia-Pacific Countries' Market for Women's Health Therapeutics, 2018-2026
  • Figure 47 : RoW Market for Women's Health Therapeutics, by Sub-region, 2018-2026
  • Figure 48 : RoW Market Shares of Women's Health Therapeutics, by Subregion, 2020
  • Figure 49 : RoW Market for Women's Health Therapeutics, 2018-2026
  • Figure 50 : RoW Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 51 : South American Market for Women's Health Therapeutics, 2018-2026
  • Figure 52 : South American Market Shares of Women's Health Therapeutics, by Disease Area, 2020
  • Figure 53 : Middle East and African Market for Women's Health Therapeutics, 2018-2026
  • Figure 54 : Global Market Shares of Women's Health Therapeutics, by Company, 2020
  • Figure 55 : AbbVie: Hematologic Oncology Annual Revenue, 2018-2020
  • Figure 56 : AbbVie Inc.: Revenue Share, by Country, 2020
  • Figure 57 : Allergan plc: Revenue Share, by Business Segment, 2017
  • Figure 58 : Amgen Oncology Pharmaceuticals: Annual Revenue, 2018-2020
  • Figure 59 : AstraZeneca's Oncology Segment: Annual Revenue, 2018-2020
  • Figure 60 : Bayer AG: Oncology Pharmaceutical Annual Revenue, 2018-2020
  • Figure 61 : Bayer AG: Revenue Share, by Region, 2018
  • Figure 62 : Bayer AG: Revenue Share, by Business Segment, 2018
  • Figure 63 : Bristol-Myers Squibb Oncology Pharmaceuticals: Annual Revenue, 2018-2020
  • Figure 64 : Daiichi Sankyo Co. Ltd.: R&D Expenditure, 2014-2016
  • Figure 65 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
  • Figure 66 : Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
  • Figure 67 : Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
  • Figure 68 : Roche: Oncology Annual Revenue, 2018-2020
  • Figure 69 : Gilead Sciences Inc.: Oncology Pharmaceutical Annual Revenue, 2018-2020
  • Figure 70 : Johnson & Johnson's Oncology Segment: Annual Revenue, 2018-2020
  • Figure 71 : Johnson and Johnson Services Inc.: Revenue Share, by Business Segment, 2018
  • Figure 72 : Johnson & Johnson Services Inc.: Revenue Share, by Region, 2018
  • Figure 73 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
  • Figure 74 : Merck & Co. Inc.: Revenue Share, by Region, 2018
  • Figure 75 : Merck & Co.'s Oncology Pharmaceutical: Annual Revenue, 2018-2020
  • Figure 76 : Novartis's Oncology Segment: Annual Revenue, 2018-2020
  • Figure 77 : Novo Nordisk: Revenue Share, by Region, 2018
  • Figure 78 : Novo Nordisk: Revenue Share, by Business Segment, 2018
  • Figure 79 : Pfizer Inc.: Oncology Segment: Annual Revenue, 2018-2020
  • Figure 80 : Pfizer Inc.: Revenue Share, by Region, 2018
  • Figure 81 : Pfizer Inc.: Revenue Share, by Business Segment, 2018
  • Figure 82 : Sanofi: Oncology Pharmaceuticals, Annual Revenue, 2018-2020
  • Figure 83 : Takeda Pharmaceutical: Oncology Annual Revenue, 2019-2021
  • Figure 84 : Rate of New Cancer Cases in the U.S., by Age Group, 2018